Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC

Executive Summary

Merck & Co just keeps clearing the hurdles to checkpoint inhibitor market domination, with EU approval in the key first-line NSCLC indication coming swiftly after the company snuck in an earlier than expected filing in the US for its chemo combination use.

Advertisement

Related Content

Under Fire, Bristol Plans To Pick Up The IO Pieces
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel